Targazyme, Inc. Receives FDA Clearance for a Phase II Haplo-Identical Transplant Study of Patients Undergoing Bone Marrow ...
SAN DIEGO, CA--(Marketwired - October 24, 2016) - Targazyme Inc., a clinical stage biopharmaceutical company developing novel enzyme technologies and products to improve clinical efficacy and cost of care outcomes for a variety of cell therapies including …